MedTrace Logo

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

NCT03689192 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-02-28

Study results available
· View outcomes & findings →

Summary

In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors. Patients will be treated with an ARG1 vaccine every third week for 45 weeks.

Conditions

Interventions

BIOLOGICAL

ARG1-18,19,20

300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Inge Marie Svane, Prof., MD · CCIT-DK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2022-01-19
Completion
2022-01-19

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03689192 on ClinicalTrials.gov